UK markets closed

Inhibikase Therapeutics, Inc. (IKT)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
1.3900+0.0500 (+3.73%)
At close: 04:00PM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
-18,817
-19,029
-18,054
-14,786
-2,848
Depreciation & amortisation
177.398
177.398
6.723
0
-
Stock-based compensation
623.634
500.148
458.147
1,532
573.695
Change in working capital
183.204
234.758
171.182
-1,764
-464.637
Accounts receivable
39.881
39.881
70.258
-110.141
0
Accounts payable
227.422
-504.406
61.395
-630.902
-247.071
Other working capital
-18,134
-18,099
-17,594
-14,297
-1,129
Other non-cash items
87.818
31.536
67
32.841
166.055
Net cash provided by operating activities
-17,891
-18,085
-17,351
-14,297
-1,129
Cash flows from investing activities
Investments in property, plant and equipment
-14.238
-14.238
-243.255
-
-
Purchases of investments
-29,426
-29,426
-20,725
0
-
Sales/maturities of investments
41,097
41,097
4,963
0
-
Net cash used for investing activities
11,657
11,657
-16,006
0
-
Cash flows from financing activities
Debt repayment
-248.911
0
-248.911
-42.534
0
Common stock issued
0
8,544
0
41,135
14,792
Other financing activities
-138.556
-138.556
-
-77.652
-
Net cash used provided by (used for) financing activities
-204.769
8,405
-204.769
41,094
15,064
Net change in cash
-39,064
1,977
-33,562
26,797
13,935
Cash at beginning of period
44,846
7,189
40,750
13,954
18.457
Cash at end of period
5,782
9,165
7,189
40,750
13,954
Free cash flow
Operating cash flow
-17,891
-18,085
-17,351
-14,297
-1,129
Capital expenditure
-14.238
-14.238
-243.255
-
-
Free cash flow
-18,134
-18,099
-17,594
-14,297
-1,129